Literature DB >> 28560064

Fms related tyrosine kinase 1 (Flt1) functions as an oncogene and regulates glioblastoma cell metastasis by regulating sonic hedgehog signaling.

Kun Jiang1, Yan-Ping Wang1, Xiao-Dong Wang1, Xiao-Bo Hui1, Lian-Shu Ding1, Ji Liu1, Dai Liu1.   

Abstract

Studies have shown that the abnormal expression of Fms related tyrosine kinase 1 (Flt1) is associated with multiple malignancies, yet its role in glioblastoma pathology remains to be elucidated. In this study, we investigated the role of Flt1 in regulating proliferation, migration and invasion of glioblastoma cells by establishing glioblastoma cell strains with constitutively silenced or elevated Flt1 expression. We demonstrate that ectopic expression of Flt1 promotes glioblastoma cells migration, invasion through cell scratching and Transwell assays. Further study has indicated that Flt1 knockdown prevents the spread of glioblastoma cells in vivo. Conversely, we also show that suppression of Flt1 expression inhibits migration and invasion of glioblastoma cells. Finally, our findings demonstrate that Flt1 promotes invasion and migration of glioblastoma cells through sonic hedgehog (SHH) signaling pathway. Our study suggests that galectin-1 represents a crucial regulator of glioblastoma cells metastasis. Thus, the detection and targeted treatment of Flt1-expressing cancer serves as a new therapeutic target for glioblastoma.

Entities:  

Keywords:  Flt1; SHH; glioblastoma; metastasis

Year:  2017        PMID: 28560064      PMCID: PMC5446481     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  27 in total

1.  FBXO31 promotes cell proliferation, metastasis and invasion in lung cancer.

Authors:  Hai-Li Huang; Yun Jiang; Ya-Hong Wang; Ting Chen; Hui-Juan He; Tie Liu; Teng Yang; La-Wei Yang; Jie Chen; Ze-Qing Song; Weimin Yao; Bin Wu; Gang Liu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin.

Authors:  Tiansuo Zhao; Wenna Jiang; Xiuchao Wang; Hongwei Wang; Chen Zheng; Yang Li; Yan Sun; Chongbiao Huang; Zhi-Bo Han; Shengyu Yang; Zhiliang Jia; Keping Xie; He Ren; Jihui Hao
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

3.  Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B.

Authors:  Haisong Xu; Yanxia Hu; Wusi Qiu
Journal:  Biomed Pharmacother       Date:  2017-01-06       Impact factor: 6.529

4.  Effect of Hedgehog Signaling Pathway Activation on Proliferation of High-Grade Gliomas.

Authors:  S A Cherepanov; K I Cherepanova; N F Grinenko; O M Antonova; V P Chekhonin
Journal:  Bull Exp Biol Med       Date:  2016-10-05       Impact factor: 0.804

5.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines.

Authors:  Jeongwu Lee; Svetlana Kotliarova; Yuri Kotliarov; Aiguo Li; Qin Su; Nicholas M Donin; Sandra Pastorino; Benjamin W Purow; Neil Christopher; Wei Zhang; John K Park; Howard A Fine
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

6.  Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Authors:  Jonas Kloepper; Lars Riedemann; Zohreh Amoozgar; Giorgio Seano; Katharina Susek; Veronica Yu; Nisha Dalvie; Robin L Amelung; Meenal Datta; Jonathan W Song; Vasileios Askoxylakis; Jennie W Taylor; Christine Lu-Emerson; Ana Batista; Nathaniel D Kirkpatrick; Keehoon Jung; Matija Snuderl; Alona Muzikansky; Kay G Stubenrauch; Oliver Krieter; Hiroaki Wakimoto; Lei Xu; Lance L Munn; Dan G Duda; Dai Fukumura; Tracy T Batchelor; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

7.  Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.

Authors:  Petra Hamerlik; Justin D Lathia; Rikke Rasmussen; Qiulian Wu; Jirina Bartkova; MyungHee Lee; Pavel Moudry; Jiri Bartek; Walter Fischer; Jiri Lukas; Jeremy N Rich; Jiri Bartek
Journal:  J Exp Med       Date:  2012-03-05       Impact factor: 14.307

Review 8.  Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy.

Authors:  Yang Yi; I-Yun Hsieh; Xiaojia Huang; Jie Li; Wei Zhao
Journal:  Front Pharmacol       Date:  2016-12-07       Impact factor: 5.810

9.  The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Francesco Marampon; Alessandro Colapietro; Simona Delle Monache; Roberta Sferra; Flora Vitale; Peter J Richardson; Lee Patient; Stephen Burbidge; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2017-01-05       Impact factor: 17.388

10.  Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells.

Authors:  Raymond Wong; Ekaterina Turlova; Zhong-Ping Feng; James T Rutka; Hong-Shuo Sun
Journal:  Oncotarget       Date:  2017-02-14
View more
  3 in total

1.  Upregulation of LINC01426 promotes the progression and stemness in lung adenocarcinoma by enhancing the level of SHH protein to activate the hedgehog pathway.

Authors:  Xiaoli Liu; Zuwei Yin; Linping Xu; Huaimin Liu; Lifeng Jiang; Shuochuan Liu; Xu Sun
Journal:  Cell Death Dis       Date:  2021-02-10       Impact factor: 8.469

Review 2.  Hedgehog signaling regulates the development and treatment of glioblastoma.

Authors:  Hongping Wang; Qun Lai; Dayong Wang; Jian Pei; Baogang Tian; Yunhe Gao; Zhaoguo Gao; Xiang Xu
Journal:  Oncol Lett       Date:  2022-07-05       Impact factor: 3.111

3.  Identification of Latent Oncogenes with a Network Embedding Method and Random Forest.

Authors:  Ran Zhao; Bin Hu; Lei Chen; Bo Zhou
Journal:  Biomed Res Int       Date:  2020-09-23       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.